253 related articles for article (PubMed ID: 18703045)
1. Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin.
Fujiwara T; Saito S; Osanai T; Kameda K; Abe N; Higuma T; Yokoyama J; Hanada H; Fukui K; Fukuda I; Okumura K
Eur J Pharmacol; 2008 Oct; 594(1-3):146-51. PubMed ID: 18703045
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
[TBL] [Abstract][Full Text] [Related]
3. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction.
Nakaya R; Uzui H; Shimizu H; Nakano A; Mitsuke Y; Yamazaki T; Ueda T; Lee JD
Int J Cardiol; 2005 Oct; 105(1):67-73. PubMed ID: 16207547
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion.
Lamparter S; Schoppet M; Christ M; Pankuweit S; Maisch B
Am J Cardiol; 2005 May; 95(9):1065-9. PubMed ID: 15842972
[TBL] [Abstract][Full Text] [Related]
5. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
[TBL] [Abstract][Full Text] [Related]
6. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.
Ichihara S; Noda A; Nagata K; Obata K; Xu J; Ichihara G; Oikawa S; Kawanishi S; Yamada Y; Yokota M
Cardiovasc Res; 2006 Feb; 69(3):726-35. PubMed ID: 16165109
[TBL] [Abstract][Full Text] [Related]
7. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
Gómez-Hernández A; Sánchez-Galán E; Ortego M; Martín-Ventura JL; Blanco-Colio LM; Tarín-Vicente N; Jiménez-Nacher JJ; López-Bescos L; Egido J; Tuñón J
Am J Cardiol; 2008 Jul; 102(1):12-8. PubMed ID: 18572029
[TBL] [Abstract][Full Text] [Related]
8. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
[TBL] [Abstract][Full Text] [Related]
9. A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery.
Sokal A; Zembala M; Radomski A; Kocher A; Pacholewicz J; Los J; Jedrzejczyk E; Zembala M; Radomski M
J Thorac Cardiovasc Surg; 2009 May; 137(5):1218-24. PubMed ID: 19379995
[TBL] [Abstract][Full Text] [Related]
10. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling.
Kameda K; Matsunaga T; Abe N; Hanada H; Ishizaka H; Ono H; Saitoh M; Fukui K; Fukuda I; Osanai T; Okumura K
Eur Heart J; 2003 Dec; 24(24):2180-5. PubMed ID: 14659769
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress activates MMP-2 in cultured human coronary smooth muscle cells.
Valentin F; Bueb JL; Kieffer P; Tschirhart E; Atkinson J
Fundam Clin Pharmacol; 2005 Dec; 19(6):661-7. PubMed ID: 16313278
[TBL] [Abstract][Full Text] [Related]
12. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
15. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity.
Taras D; Blanc JF; Rullier A; Dugot-Senant N; Laurendeau I; Vidaud M; Rosenbaum J
J Hepatol; 2007 Jan; 46(1):69-76. PubMed ID: 16935385
[TBL] [Abstract][Full Text] [Related]
16. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart.
Lalu MM; Pasini E; Schulze CJ; Ferrari-Vivaldi M; Ferrari-Vivaldi G; Bachetti T; Schulz R
Eur Heart J; 2005 Jan; 26(1):27-35. PubMed ID: 15615796
[TBL] [Abstract][Full Text] [Related]
17. Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stress.
Saito S; Fujiwara T; Matsunaga T; Minagawa K; Fukui K; Fukuda I; Osanai T; Okumura K
Atherosclerosis; 2008 Aug; 199(2):378-83. PubMed ID: 18164019
[TBL] [Abstract][Full Text] [Related]
18. Effects of pravastatin on the function of dendritic cells in patients with coronary heart disease.
Li X; Liu C; Cui J; Dong M; Peng CH; Li QS; Cheng JL; Jiang SL; Tian Y
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):101-6. PubMed ID: 19143751
[TBL] [Abstract][Full Text] [Related]
19. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
Fiotti N; Altamura N; Orlando C; Simi L; Reimers B; Pascotto P; Zingone B; Pascotto A; Serio M; Guarnieri G; Giansante C
Int J Cardiol; 2008 Jul; 127(3):350-7. PubMed ID: 17706812
[TBL] [Abstract][Full Text] [Related]
20. Serum lipids and cardiac function correlate with nitrotyrosine and MMP activity in coronary artery disease patients.
Bencsik P; Sasi V; Kiss K; Kupai K; Kolossváry M; Maurovich-Horvat P; Csont T; Ungi I; Merkely B; Ferdinandy P
Eur J Clin Invest; 2015 Jul; 45(7):692-701. PubMed ID: 25944577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
